Knight And TherapeuticsMD Announce Filing Of New Drug Submission For Joyesta In Canada

Author: Benzinga Newsdesk | October 30, 2019 05:40pm

Knight Therapeutics Inc. (TSX:GUD) ("Knight") and TherapeuticsMD, Inc. (NASDAQ:TXMD) ("TherapeuticsMD") announced today that Knight's New Drug Submission (NDS) for Joyesta™ has been accepted for review by Health Canada. Joyesta, licensed from TherapeuticsMD, is an applicator-free estradiol softgel vaginal capsule for the treatment of postmenopausal symptoms of vulvar and vaginal atrophy due to estrogen deficiency. Joyesta is marketed as IMVEXXY® (estradiol vaginal inserts) by TherapeuticsMD in the U.S., for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.

Posted In: TSX:GUD TXMD